Exploring the Potential of Young Blood Transfusions in Slowing the Aging Process

Blood Transfusions: “Blood Transformation for Eternal Youth: Unraveling the Ethical Dilemmas of Youthful Blood Infusion”

In an episode of the television series Silicon Valley titled “The Blood Boy,” a tech mogul employs a young assistant for blood transfusions in an attempt to combat ageing. This pursuit of eternal youth through bathing in or imbibing the blood of the young echoes back to centuries-old practices, such as Pope Innocent VIII’s futile endeavour in the 1490s, where he allegedly consumed the blood of three ten-year-old boys, resulting in their tragic demise.

Is there any scientific merit to these practices? While infusing young blood did not significantly impact overall lifespan, experiments involving the transfusion of young animal blood into older subjects demonstrated rejuvenating effects on various organs. This concept aligns with the age-old practice of parabiosis, as discussed in a previous video. Interestingly, infusing young human blood, sourced from umbilical cords, into mice (genetically modified to accept foreign tissue) has shown promise in addressing age-related cognitive dysfunction. Clinical trials are now exploring weekly infusions of young blood products in patients with mild to moderate Alzheimer’s disease.

Surprisingly, injecting blood from young mice into older ones enhances memory and learning, indicating a potential youth-restoring factor. Conversely, injecting old blood into young mice worsens cognitive functions, hinting at a potential ageing factor. UC Berkeley researchers took a groundbreaking approach by diluting the blood of old mice through plasma removal and replacing half with water. The results were astonishing: rejuvenation in the liver, muscles, and brain rivalled or exceeded traditional parabiosis or transfusions. This suggests that dilution, rather than the introduction of young blood, could be the key to these benefits.

This discovery is particularly significant as it aligns with an existing FDA-approved procedure called therapeutic plasma exchange. Originally designed to filter toxins or autoimmune antibodies, researchers tested its efficacy in diluting old blood to treat Alzheimer’s disease. In a randomized trial, moderate Alzheimer’s patients undergoing the real procedure experienced approximately 60% less cognitive and functional decline over 14 months compared to those receiving a placebo. This outperformed traditional Alzheimer’s treatments like the drug memantine, offering a potential breakthrough in the quest for effective interventions. As a Director of an Institute of Biomedical Ethics pointed out, this approach avoids the unsettling notion of the old feeding on the young, marking a promising step forward in ethical medical practices.

#Transfusions #Young #Blood #Slow #Aging
Source link